4d Pharma PLC Director/PDMR Shareholding (5885G)

TIDMDDDD

RNS Number : 5885G

4d Pharma PLC

18 March 2020

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

 
 Name                                Shares   % of total          Shares   % of total 
                               in 4D pharma       shares    in 4D pharma       shares 
                                 plc before     in issue       plc after     in issue 
                                   purchase                     purchase 
 
 David Norwood (Chairman)         8,457,061         7.7%       8,557,061         7.8% 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                            David Norwood 
     ------------------------------  -------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position/status                 Chairman/ PDMR 
     ------------------------------  -------------------------------- 
 b)   Initial notification            Initial notification 
       /Amendment 
     ------------------------------  -------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------- 
 a)   Name                            4D Pharma plc 
     ------------------------------  -------------------------------- 
 b)   LEI                             213800O49VYSXWE2ZD52 
     ------------------------------  -------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------- 
 a)   Description of the              Ordinary shares of GBP0.0025 
       financial instrument, 
       type of instrument              ISIN: GB00BJL5BR07 
       Identification code 
     ------------------------------  -------------------------------- 
 b)   Nature of the transaction       Purchase of Ordinary Shares 
     ------------------------------  -------------------------------- 
 c)   Price(s) and volume(s)            Price(s)   Volume(s) 
                                         28p        100,000 
                                                   ---------- 
     ------------------------------  -------------------------------- 
 d)   Aggregated information 
       - Aggregated volume              N/A 
       - Price 
     ------------------------------  -------------------------------- 
 e)   Date of the transaction         17(th) March 2020 
     ------------------------------  -------------------------------- 
 f)   Place of the transaction        London Stock Exchange, AIM 
     ------------------------------  -------------------------------- 
 
 
 
 
 
 
For further information please contact: 
4D 
 Duncan Peyton, Chief Executive Officer 
  [e-mail]                          + 44 (0)113 895 0130 
 N+1 Singer - Nominated Adviser and Joint 
  Broker                                      [phone] 
 Aubrey Powell / Justin McKeegan / Alex Bond 
  (Corporate Finance) 
  Tom Salvesen (Corporate Broking) 
 Bryan Garnier & Co. Limited - Joint Broker   [phone] 
 Dominic Wilson / Phil Walker 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAXDPFLKEEEA

(END) Dow Jones Newswires

March 18, 2020 03:49 ET (07:49 GMT)